Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>This is our first report on Royalty Pharma Plc.</li>
<li>Royalty Pharma has recently announced that it has acquired royalty interest in Gavreto from Blueprint Medicines for up to $340 million.</li>
<li>Additional royalty interests have been acquired by Royalty Pharma in Orladeyo and BCX9930 from BioCryst Pharmaceuticals.</li>
</ul>


This is our first report on Royalty Pharma Plc.
Royalty Pharma has recently announced that it has acquired royalty interest in Gavreto from Blueprint Medicines for up to $340 million.
Additional royalty interests have been acquired by Royalty Pharma in Orladeyo and BCX9930 from BioCryst Pharmaceuticals.


Royalty Pharma plc: Initiation of Coverage – Financial Forecasts

United States

Royalty Pharma plc acquires biopharmaceutical royalties. The Company funds innovation directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Royalty Pharma (RPRX US)

Royalty Pharma plc: Initiation of Coverage – Financial Forecasts

This is our first report on Royalty Pharma Plc. Royalty Pharma has recently announced that it has acquired royalty interest in Gavreto from...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)